📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. (2013)

First Author: Sale MJ
Attributed to:  How does ERK1/2-dependent phosphorylation target BimEL to the proteasome? funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1042/bj20121212

PubMed Identifier: 23234544

Publication URI: http://europepmc.org/abstract/MED/23234544

Type: Journal Article/Review

Volume: 450

Parent Publication: The Biochemical journal

Issue: 2

ISSN: 0264-6021